<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02913066</url>
  </required_header>
  <id_info>
    <org_study_id>XDu</org_study_id>
    <nct_id>NCT02913066</nct_id>
  </id_info>
  <brief_title>S-1 IMRT Versus S-1 and Cisplatin Concurrent IMRT in Inoperable Esophageal Squamous Cell Carcinoma</brief_title>
  <official_title>Prospective, Randomized, Multicenter, Phase II Noninferiority Study of S-1 Concurrent Intensity-modulated Radiation Therapy (IMRT) Versus S-1 and Cisplatin Concurrent IMRT in Inoperable Esophageal Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mianyang Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mianyang Central Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Will meet the inclusion criteria of patients with esophageal squamous cell carcinoma, divided&#xD;
      into 2 groups randomly:&#xD;
&#xD;
      Experimental group: radiotherapy combined with S-1 chemotherapy.&#xD;
&#xD;
      Control group: radiotherapy combined with S-1 chemotherapy and cisplatin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Will meet the inclusion criteria of patients with unresectable esophageal squamous cell&#xD;
      carcinoma, divided into 2 groups randomly:&#xD;
&#xD;
      Experimental group: radiotherapy combined with S-1 chemotherapy;&#xD;
&#xD;
      control group: radiotherapy combined with S-1 chemotherapy for first to 14 days and 29 ~ 42&#xD;
      days, plus cisplatin first 1~ 4 days and 29 ~ 33 days. Using IMRT radiotherapy.&#xD;
&#xD;
      Two weeks after radiotherapy finish, two cycle adjuvant chemotherapy with S-1 70 mg/m2 1~ 14&#xD;
      days, or S-1 70 mg/m2 1~ 14 days, plus cisplatin 25mg/m2 1~ 4 days, 21 days for a cycle.&#xD;
&#xD;
      Primary Outcome Measure is complete remission rate.&#xD;
&#xD;
      Secondary Outcome Measures are overall survival (OS) and Progression-Free-Survival (PFS) and&#xD;
      toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Remission Rate (CR)</measure>
    <time_frame>Three months after radiotherapy finished</time_frame>
    <description>Complete response rate of primary tumor which will be measured by endoscopy and computer tomography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Two years after adjuvant chemotherapy finished</time_frame>
    <description>The time from treatment completion to patient death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free-Survival (PFS)</measure>
    <time_frame>Two years after adjuvant chemotherapy finished</time_frame>
    <description>The time from treatment completion to disease progression</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Single drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>S-1 concurrent Radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Double drug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>S-1 plus cisplatin concurrent Radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>S-1 concurrent radiotherapy</intervention_name>
    <description>Radiotherapy 60~66 Gray/28~33 times (50.4~60 Gray /28~33 planning target volume times, 60~66 Gray/28~33 Gross tumor volume of primary tumor), synchronous chemotherapy S-1 70 mg/m2 5 to 1 per week, to the end of radiotherapy. Two weeks after radiotherapy finish, two cycle adjuvant chemotherapy with S-1, 70 mg/m2, 1~ 14 days, 21 days for a cycle.</description>
    <arm_group_label>Single drug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>S-1 plus Cisplatin concurrent radiotherapy</intervention_name>
    <description>Radiotherapy 60~66 Gray/28~33 times (50.4~60 Gray /28~30 planning target volume times, Gross tumor volume of primary tumor60~66 Gray/28~33), synchronous chemotherapy S-1 70 mg/m2 1~ 14 days and 29 to 42 days, plus cisplatin 25mg/m2 1~ 4 days and 29 to 33 days. Two weeks after radiotherapy finish, two cycle adjuvant chemotherapy with S-1 70 mg/m2 1~ 14 days, plus cisplatin 25mg/m2 1~ 4 days, 21 days for a cycle.</description>
    <arm_group_label>Double drug</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histology or cytology confirmed esophageal squamous cell carcinoma.&#xD;
&#xD;
          2. There are measurable lesions in the RECIST standard.&#xD;
&#xD;
          3. American Joint Committee on Cancer/Union Internationale Contre le Cancer esophageal&#xD;
             cancer staging (Sixth Edition) clinical stage II a~ IV B period.&#xD;
&#xD;
          4. Age younger than 75 years old.&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group physical status score was 0 ~ 1.&#xD;
&#xD;
          6. No esophageal perforation and active esophageal bleeding, no obvious trachea, thoracic&#xD;
             major vascular invasion.&#xD;
&#xD;
          7. Chest chemotherapy and radiotherapy, immunotherapy or biologic therapy have not been&#xD;
             performed before.&#xD;
&#xD;
          8. Serum hemoglobin is&lt;100g/L, platelet&gt;100 * 109/L,Absolute neutrophil count&gt;1.5 *&#xD;
             109/L.&#xD;
&#xD;
          9. Cr≤1.25 upper normal limit or CCr≥60 mL/min.&#xD;
&#xD;
         10. Serum bilirubin ≤1.5 times upper normal limit, Aspartate transaminase (SGOT) and&#xD;
             Alanine aminotransferase (SGPT) ≤ 2.5 times upper normal limit,Alkaline phosphatase≤ 5&#xD;
             times upper normal limit.&#xD;
&#xD;
         11. A history of interstitial pneumonia and interstitial pneumonia.&#xD;
&#xD;
         12. FEV1&gt;0.8 liters.&#xD;
&#xD;
         13. Patients or family members signed a formal informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior to the start of the trial had received thoracic radiotherapy, chemotherapy or&#xD;
             surgical resection of esophageal cancer.&#xD;
&#xD;
          2. Primary lesions were multifocal esophageal cancer patients, the lower bound of&#xD;
             esophageal primary lesions was less than 3cm.&#xD;
&#xD;
          3. Patients with severe cardiovascular or pulmonary disease, interstitial pneumonia or a&#xD;
             history of interstitial pneumonia.&#xD;
&#xD;
          4. Patients with distant metastases.&#xD;
&#xD;
          5. There were obvious esophageal ulcer, chest and back with moderate pain, and the&#xD;
             symptoms of esophageal perforation.&#xD;
&#xD;
          6. Can't understand the test requirements, or patients may not comply with the&#xD;
             requirements of the test.&#xD;
&#xD;
          7. There are other malignant lesion patients, but can cure skin cancer (non melanoma),&#xD;
             cervical carcinoma in situ or malignant disease cured except for more than 5 years.&#xD;
&#xD;
          8. An allergic reaction known to have 3 or 4 levels of any treatment.&#xD;
&#xD;
          9. Had participated in other clinical trials in the past 30 days.&#xD;
&#xD;
         10. The researchers believe that some of the obvious diseases that should be excluded from&#xD;
             this study are excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bo Du X, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mianyang Central Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bo Du X, Doctor</last_name>
    <phone>+8613550822229</phone>
    <email>duxiaobo2005@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xue W Y, Student</last_name>
    <phone>+8615181958867</phone>
    <email>532995900@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Xiaobo du</name>
      <address>
        <city>Mianyang</city>
        <state>Sichaung</state>
        <zip>621000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xaiobo Du, MD</last_name>
      <phone>+86 08162230478</phone>
      <email>duxiaobo2005@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>September 20, 2016</study_first_submitted>
  <study_first_submitted_qc>September 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2016</study_first_posted>
  <last_update_submitted>June 14, 2017</last_update_submitted>
  <last_update_submitted_qc>June 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mianyang Central Hospital</investigator_affiliation>
    <investigator_full_name>Xiaobo Du</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

